For over 27 years, Andrew has achieved a significant track record of success within three critical areas of healthcare innovation: overseeing yhe development and commercialization of novel therapeutics and medical technologies from inception to NDA approval.

Prior to Health Innovation Capital, Andrew was a Partner at Excelyrate Capital Fund I. In addition, he served as a Principal investor with Essex Woodlands, the Michigan Economic Development Corp’s Life Science Venture Fund, and Excelyrate Capital, Andrew’s investing experience included the execution of 11 investments with 10 Exits that achieved a track record for providing significant collective net cash on cash returns for investors.

Andrew’s tenure as a senior healthcare financial, business development and commercial strategy executive includes multinational experiences in both Large Cap pharma (Baxter) and rapid growth venture backed biotech and medtech companies including SkinAxis (SVP Commercial Operations and Corp. Strategy) and Conceivex, Inc. (Chief Strategy and Business Development Officer).

Andrew is a frequent speaker on international pediatric health innovation and venture capital investment strategies targeting this patient population.  In addition, Andrew has worked with the National Institute of Health (NIH) and nationally recognized indication specific advocacy groups.

‍